title: Safety and effectiveness of teriparatidevsalendronate in postmenopausal osteoporosis: a prospective non randomized clinical study.
abstract: In this work we study the safety and effectiveness of teriparatide and alendronate in patients with postmenopausal osteoporosis at high risk of fracture; it was a double-blinded and it was done by examining the comparisons between teriparatide 20 μg/day and alendronate 10 mg/day. Safety and effectiveness analyses were based on data from 355 woman with a mean age of 68 years. Two groups (A and B) with T-score ≤-2.5 at bone mineral density were analyzed and 3 or more vertebral fractures on radiograph. Group A: was treated with teriparatide 20 μg/day and composed from 182 women, in post-menopausal age, without a history of cancer. Group B: was treated with alendronate 10 mg/day composed from 173 women, postmenopausal age, with previous history of cancer (non-active during the study). Clinical evaluations were on bone turnover markers (alkaline phosphatase, procollagene type 1N-terminal propeptide, andN-telopeptide cross-links), dual-energy X-ray absorptiometry and health-related quality of life (HrQoL). Safety was assessed by reporting of adverse drug reactions (ADRs). The results of this study imply that teriparatide comparated with alendronate has a favorable safety profile and is effective in the treatment of patients with osteoporosis at high risk of fracture.
authors.affiliation: Orthopaedic Department, University of Sassari, Sassari, Italy.
authors.forename: Gianfilippo
authors.initials: G
authors.lastname: Caggiari
authors.affiliation: Orthopaedic Department, University of Sassari, Sassari, Italy.
authors.forename: Paolo Tranquilli
authors.initials: PT
authors.lastname: Leali
authors.affiliation: Orthopaedic Department, University of Sassari, Sassari, Italy.
authors.forename: Giulia Raffaella
authors.initials: GR
authors.lastname: Mosele
authors.affiliation: Orthopaedic Department, University of Sassari, Sassari, Italy.
authors.forename: Leonardo
authors.initials: L
authors.lastname: Puddu
authors.affiliation: Department of Clinical Endocrinology, University of Sassari, Sassari, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Badessi
authors.affiliation: Orthopaedic Department, University of Sassari, Sassari, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: Doria
keywords: alendronate; bone mineral density; osteoporosis; teriparatide; vertebral fracture